CD8A and neoplasm: For instance, single-cell RNA sequencing recently showed high expression of Lymphocyte Activating 3 (LAG3) in NKT/CD8+ T-cells in ESCC samples, supporting a potential role for anti-LAG3 treatments (a novel class of immune checkpoint inhibitors) in this tumor type [186].